Skip to main content
Kidney International Reports logoLink to Kidney International Reports
letter
. 2018 Oct 1;4(1):184–185. doi: 10.1016/j.ekir.2018.09.018

Taqman Assay for Genotyping CKD-Associated APOL1 SNP rs60910145: A Cautionary Note

Victor A David 1, Elizabeth A Binns-Roemer 2, Cheryl A Winkler 2,
PMCID: PMC6308993  PMID: 30596185

To the Editor:

There are 2 APOL1 variant haplotypes, G1 and G2, that predispose individuals of African descent to a diverse spectrum of chronic kidney disease in the homozygous (G1/G1 or G2/G2) or compound heterozygous state (G1/G2).1, 2 The G1 haplotype (approximately 23% of African Americans) carries 2 nonsynonymous variants: rs73885319 (p.S342G) and rs60910145 (p.I384M). Genotyping rs73885319 is generally sufficient, as the 2 single-nucleotide polymorphisms (SNPs) are in near-absolute linkage disequilibrium; however, researchers often genotype both G1 variants for quality control purposes and to distinguish between 2 G1 sub-haplotypes: G1GM (has both S242G and I384M amino acid substitutions) and the rare G1G+ (only the S242G substitution).2 The G2 haplotype harbors a 6–base pair in-frame deletion (rs71785313, also known as rs143830837, approximate 13% frequency in African Americans). We use custom Taqman assays for these SNPs: rs73885319 (Assay ID-AH20SD1), rs60910145 (Assay ID-AHWR1JA), and RS71785313 (Assay ID-AH1RT7T). Many laboratories type the APOL1 SNPs using Taqman assays that are available from ThermoFisher Scientific (Waltham, MA) as predesigned assays. The ThermoFisher Web site notes that one of the polymerase chain reaction primers for rs60910145 (Assay ID-C__89555688_10) spans the 6–base pair deletion of the G2 SNP. We found that the presence of the 6–base pair deletion results in a failure of amplification of the rs60910145 allele on the G2 haplotype. Thus, the G2/G2 haplotype will fail to amplify for rs60910145, and G1GM/G2 individuals will fail to amplify the rs60910145 allele on the G2 haplotype and be scored as homozygous for the variant nucleotide instead of heterozygous (Table 1). Although the G2 SNP is absent or rare in Asian and white individuals, and thus will not affect RS60910145 typing in those populations, most investigators are typing RS60910145 in populations of African descent in which G2 is much more common. We have typed a set of 1110 African American samples with the 2 different versions of the rs60910145 assay, as well as rs73885319 and rs143830837, and confirmed this result (7.3% of the rs60910145 genotypes obtained with the predesigned assay failed or gave the incorrect genotype). Specifically, with the predesigned assay, 1.4% of the samples tested had a G2/G2 genotype, so the RS60910145 amplification failed, and 5.9% of the samples had the G1GM,G2 genotype, and they were incorrectly typed as G instead of GT at RS60910145. When the incorrect RS60910145 result for the G1GM,G2 genotype samples is combined with results from the rs73885319 and rs71785313 SNP assays, it will result in an inferred haplotype never actually observed on African chromosomes. (Table 2)

Table 1.

Taqman SNP typing with the predesigned rs60910145 (C__89555688_10) assay results in errors in some individuals with the G2 allele: haplotypea

RS73885319 (p.S242G) RS60910145 (p.I384M) RS71785313 (p.N388_Y389del) Amplification of RS60910145 with predesigned primer
Haplotype
G0 A T I Yes
G1GM G G I Yes
G1G+ G T I Yes
G2 A T D No
a

Derived allele in bold.

Table 2.

Taqman SNP typing with the predesigned rs60910145 (C__89555688_10) assay results in errors in some individuals with the G2 allele: genotypes observed in a survey population of 1110 African American samples

Genotype rs60910145 assay
Frequency observed, %
Custom assay Predesigned assay
G0,G0 T T 47.5
G0,G1GM GT GT 25.7
G0,G1G+ T T 0.3
G1GM,G1GM G G 4.1
G1GM,G1G+ GT GT 0.5
G0,G2 T T 14.5
G1GM,G2 GT Ga 5.9
G2,G2 T No amplification 1.4
a

When combined with results from the rs73885319 and rs71785313 SNP assays, will result in an inferred haplotype not observed on African chromosomes.

It is important to avoid the rs71785313 deletion while designing genotyping probes or primers for the APOL1 region. ThermoFisher has been made aware of this problem and plans to replace the commercial assay for rs60910145 with the custom-designed assay (Assay ID-AHWR1JA). Investigators who have used the ThermoFisher predesigned assay are cautioned that rs60910145 results using the predesigned ThermoFisher assay are not reliable. It is difficult to ascertain from the literature which Taqman assay investigators use, because they do not typically report the part number for the RS60910145 assay. Although the custom-designed assay for rs60910145 is not listed on the ThermoFisher Web site, it can be purchased by specifying RS60910145 Assay ID-AHWR1JA.

Acknowledgments

The project has been supported in part the National Institutes of Health and the National Cancer Institute Intramural Research Program (CAW) and under contract HHSN26120080001E (CAW). The content of this publication does not necessarily reflect the view or policy of the Department of Health and Human Services, nor does mention of trade names, commercial products or organizations imply endorsement by the government.

References

  • 1.Genovese G., Friedman D.J., Ross M.D. Association of trypanolytic ApoL1 variants with kidney disease in African Americans. Science. 2010;329:841–845. doi: 10.1126/science.1193032. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Kopp J.B., Nelson G.W., Sampath K. APOL1 genetic variants in focal segmental glomerulosclerosis and HIV-associated nephropathy. J Am Soc Nephrol. 2011;22:2129–2137. doi: 10.1681/ASN.2011040388. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Kidney International Reports are provided here courtesy of Elsevier

RESOURCES